» Articles » PMID: 27529218

Role of Toll-Like Receptor Signaling in the Pathogenesis of Graft-versus-Host Diseases

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2016 Aug 17
PMID 27529218
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Graft-versus-host disease (GVHD) and infection are major complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and the leading causes of morbidity and mortality in HSCT patients. Recent work has demonstrated that the two complications are interdependent. GVHD occurs when allo-reactive donor T lymphocytes are activated by major histocompatibility antigens or minor histocompatibility antigens on host antigen-presenting cells (APCs), with the eventual attack of recipient tissues or organs. Activation of APCs is important for the priming of GVHD and is mediated by innate immune signaling pathways. Current evidence indicates that intestinal microbes and innate pattern-recognition receptors (PRRs) on host APCs, including both Toll-like receptors (TLRs) and nucleotide oligomerization domain (NOD)-like receptors (NLRs), are involved in the pathogenesis of GVHD. Patients undergoing chemotherapy and/or total body irradiation before allo-HSCT are susceptible to aggravated gastrointestinal epithelial cell damage and the subsequent translocation of bacterial components, followed by the release of endogenous dangerous molecules, termed pathogen-associated molecular patterns (PAMPs), which then activate the PRRs on host APCs to trigger local or systemic inflammatory responses that modulate T cell allo-reactivity against host tissues, which is equivalent to GVHD. In other words, infection can, to some extent, accelerate the progression of GVHD. Therefore, the intestinal flora's PAMPs can interact with TLRs to activate and mature APCs, subsequently activate donor T cells with the release of pro-inflammatory cytokines, and eventually, induce GVHD. In the present article, we summarize the current perspectives on the understanding of different TLR signaling pathways and their involvement in the occurrence of GVHD.

Citing Articles

Targeting the chemokines in acute graft-versus-host disease.

Xu Z, Wang H Front Immunol. 2025; 15():1525244.

PMID: 39840040 PMC: 11747407. DOI: 10.3389/fimmu.2024.1525244.


Global Down-regulation of Gene Expression Induced by Mouse Mammary Tumor Virus (MMTV) in Normal Mammary Epithelial Cells.

Ahmad W, Panicker N, Akhlaq S, Gull B, Baby J, Khader T Viruses. 2023; 15(5).

PMID: 37243196 PMC: 10223558. DOI: 10.3390/v15051110.


Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells.

Mestre-Duran C, Martin-Cortazar C, Garcia-Solis B, Pernas A, Pertinez L, Galan V Front Immunol. 2023; 13:1045316.

PMID: 36685552 PMC: 9851469. DOI: 10.3389/fimmu.2022.1045316.


Roles of the intestinal microbiota and microbial metabolites in acute GVHD.

Lin D, Hu B, Li P, Zhao Y, Xu Y, Wu D Exp Hematol Oncol. 2021; 10(1):49.

PMID: 34706782 PMC: 8555140. DOI: 10.1186/s40164-021-00240-3.


Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia.

Kim S, Santhanam S, Lim S, Choi J Int J Mol Sci. 2020; 21(12).

PMID: 32560120 PMC: 7349873. DOI: 10.3390/ijms21124281.


References
1.
Smirnova I, Hamblin M, McBride C, Beutler B, Di Rienzo A . Excess of rare amino acid polymorphisms in the Toll-like receptor 4 in humans. Genetics. 2001; 158(4):1657-64. PMC: 1461767. DOI: 10.1093/genetics/158.4.1657. View

2.
Zeiser R . Activation of Innate Immunity in Graft-versus-Host Disease: Implications for Novel Targets?. Oncol Res Treat. 2015; 38(5):239-43. DOI: 10.1159/000381296. View

3.
Taylor P, Ehrhardt M, Lees C, Panoskaltsis-Mortari A, Krieg A, Sharpe A . TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood. 2008; 112(8):3508-16. PMC: 2569186. DOI: 10.1182/blood-2007-09-113670. View

4.
Duramad O, Fearon K, Chang B, Chan J, Gregorio J, Coffman R . Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol. 2005; 174(9):5193-200. DOI: 10.4049/jimmunol.174.9.5193. View

5.
Reikine S, Nguyen J, Modis Y . Pattern Recognition and Signaling Mechanisms of RIG-I and MDA5. Front Immunol. 2014; 5:342. PMC: 4107945. DOI: 10.3389/fimmu.2014.00342. View